Tag:
Cipla
Latest Headlines
Latest Headlines
India's Supreme Court allows Cipla move in Roche patent case
The Supreme Court of India will allow a scientist to join the patent case involving Indian drug giant Cipla which had earlier been found to have violated the Roche patent on its Tarceva (erlotinib) cancer drug.
Indian firms in a race to buy Nasdaq-listed Sagent, report says
A slew of Indian drugmakers are in a race to buy U.S.-based Sagent Pharmaceuticals, the Economic Times reports, suggesting a price tag north of $500 million and competition between large generics companies and private equity.
Cipla chairman raising holding as company transitions leadership
Y.K. Hamied, the nonexecutive chairman of Indian pharma giant Cipla, is taking his stake in the company to more than 20% at the end of this month as the company prepares for new leadership.
With most sanctions lifted, Novo ahead of the pack in Iran
International pharma giants looking to make inroads into the Iranian market are going to find at least two drug companies standing in their way--Novo and Cipla--which have maintained a presence in the country while Western sanctions ate away at the rest of the economy.
Cipla says top 50 drugs in development could bring in $30B
Indian drugmaker Cipla said it currently has 200 drugs in development and that the top 50 of those drugs have the potential to earn the company more than $30 billion.
Cipla says top 50 drugs in development could bring in $30B
Indian drugmaker Cipla said it currently has 200 drugs in development and that the top 50 of those drugs have the potential to earn the company more than $30 billion.
Management theory put in play as India's Cipla eyes expansion abroad
A new management structure at Mumbai-based Cipla promises a high-stakes effort to help the Indian drugmaker abroad after an active spurt of acquisitions in 2015 as well as management shuffles.
Roche resolves patent war with India's Glenmark over generic Tarceva
Roche is burying the hatchet with India's Glenmark in a patent war over its cancer drug Tarceva, settling outstanding litigation with the company even as it wages a battle with another Indian generics maker over a patent for the med.
Don't count India out yet in biosimilars race, Quintiles exec says
The globe's largest clinical research organization is looking to India as a source for the next waves of biosimilars as $55 billion worth of biotech drugs face patent expirations.
Delhi court rules against Cipla's copy of Roche's Tarceva but allows sales to continue
Indian drug giant Cipla caught a break of sorts when a court in New Delhi ruled that while the company had infringed the patent held by Roche on the lung cancer drug Tarceva (erlotinib hydrochloride), Cipla can continue selling its copy in light of the fact the patent expires in March 2016.
